Bayer may be next in line for anticoagulant lawsuits

Now it is Bayer’s turn. Less than a month after Boehringer Ingelheim set aside $650 million to settle lawsuits in the U.S. over its anticoagulant dabigatran (Pradaxa), rival Bayer received its first round of similar claims over rivaroxaban (Xarelto), according to the Frankfurter Allgemeine Zeitung newspaper.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup